From: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
 | Placebo (n = 46) | Givosiran (n = 48) | Total (N = 94) |
---|---|---|---|
Antidepressants | |||
 Benzodiazepine derivatives | 10 (22) | 10 (21) | 20 (21) |
 Benzodiazepine-related drugs | 3 (7) | 4 (8) | 7 (7) |
 Other anti-depressants | 4 (9) | 9 (19) | 13 (14) |
 SSRIs | 2 (4) | 4 (8) | 6 (6) |
Antihypertensives | |||
 ACE inhibitors | 2 (4) | 1 (2) | 3 (3) |
 Angiotensin II receptor antagonists | 3 (7) | 2 (4) | 5 (5) |
 Beta blocking agents, non-selective | 1 (2) | 3 (6) | 4 (4) |
 Beta blocking agents, selective | 5 (11) | 7 (15) | 12 (13) |
Antiemetics | |||
 5HT3 antagonists | 12 (26) | 12 (25) | 24 (26) |
Pain medications | |||
 Natural opium alkaloids | 27 (59) | 23 (48) | 50 (53) |
 Opioid anesthetics (fentanyl) | 2 (4) | 0 | 2 (2) |
 Opioid/non-opioid combinations | 2 (4) | 5 (10) | 7 (7) |
 Opium alkaloid derivatives | 2 (4) | 0 | 2 (2) |
 Other opioids | 8 (17) | 6 (13) | 14 (15) |
 Other analgesics and antipyretics | 10 (22) | 13 (27) | 23 (25) |